Publication of Annual Report and Notice of AGM
Updated : 14:58
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or the "Company")
Publication of Annual Report and Notice of AGM
Alderley Park, 31st March 2023 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies with improved tolerability and anti-cancer activity, announces that its annual report and financial statements for the year ended 31 December 2022 ("Annual Report and Accounts") are now available for download on the Company's website at https://www.bivictrix.com/investor-centre; and confirms the date for its Annual General Meeting ("AGM").
Copies of the Annual Report and Accounts and the Notice of AGM will also be mailed to shareholders, who have elected to opt out on receiving electronic communications, later today.
The Company will hold its AGM on 4th May 2023 at 11.30 am BST at the Company's registered office, Mereside Alderley Park, Alderley Edge, Manchester, SK10 4TG.
For more information, please contact:
| ||||||||||||||||||||||||||||
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.
The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.
BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.